Form 8-K Aclaris Therapeutics, For: Nov 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Form 8-K Aclaris Therapeutics, For: Nov 16
November 19, 2024 11:07 AM EST
Goldman Comments on Aclaris Therapeutics (NASDAQ: ACRS)
The analyst comments "This morning, ACRS announced it has entered into a license agreement with Biosion for global rights (excluding China) to BSI-045B (also known as TQC2731), an anti-TSLP monoclonal antibody (mAb), and BSI-502, an anti-TSLP plus anti-IL4R... More
November 19, 2024 7:06 AM EST
(Updated - November 19, 2024 7:19 AM EST)
Leerink Partners analyst Thomas J. Smith upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform with a price target of $7.00 (from $2.00).
The analyst comments "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT... More
November 18, 2024 2:54 PM EST
Piper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 (from $3.00).
The analyst comments "Upgrading ACRS shares to Overweight after what we see as a transformative deal to acquire two novel I&I... More
November 18, 2024 12:34 PM EST
Stifel analyst Alex Thompson reiterated a Hold rating and $3.00 price target on Aclaris Therapeutis (NASDAQ: ACRS)
The analyst comments "Aclaris announced a licensing agreement with Biosion to acquire ex-China rights to a clinical stage TSLP mAb (BSI-045B) and a preclinical TSLPxIL-4R bispecific (BSI-502). The... More
